Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
The startup plans to use the funding to continue developing its technology and to position it as an innovator in ophthalmology. Eyevensys’ tech is a gene therapy platform to deliver ocular drugs via an electrotransfection system to the ciliary muscle of the eye.
You’ll also find out why the Association for Research in Vision and Ophthalmology has honored a professor at the UNT Health Science Center in Fort Worth in this roundup of research and development activity in North Texas.
“A car isn’t just a car today. New vehicles offer systems and components that deliver enhanced computing power but also broaden the cyber-attack surface.”
Brian Gorenc VP of Threat Research
Trend Micro
.…on...
Throw a rock in North Texas—or Silicon Valley or Austin or NYC—and chances are you’ll hit someone who’s working on an AI breakthrough. But please don’t do that. It wouldn’t be nice, and according to the U.S....
“A car isn’t just a car today. New vehicles offer systems and components that deliver enhanced computing power but also broaden the cyber-attack surface.”
Brian Gorenc VP of Threat Research
Trend Micro
.…on...
Throw a rock in North Texas—or Silicon Valley or Austin or NYC—and chances are you’ll hit someone who’s working on an AI breakthrough. But please don’t do that. It wouldn’t be nice, and according to the U.S....